ArticleRevista brasileira de hematologia e hemoterapia
Resistance of dialyzed patients to erythropoietin.
Article in Revista brasileira de hematologia e hemoterapia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Mixed hemodiafiltration reduces erythropoiesis stimulating agents requirement in dialysis patients: a prospective randomized study.Journal of nephrology · 2020Trial
- Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019Trial
- Current research on the HIF-2α-EPO-Hb axis in hypoxic environments: from molecular mechanisms to clinical.Frontiers in medicine · 2026Review
- Comparison of the Diagnostic Efficacy of Anemia Indices in Patients Undergoing Hemodialysis and Peritoneal Dialysis.International journal of preventive medicine · 2026Article
- Association Between Telomere Shortening and Erythropoietin Resistance in Patients with Chronic Kidney Disease Undergoing Hemodialysis.International journal of molecular sciences · 2025Observational
- Gut microbial metabolites SCFAs and chronic kidney disease.Journal of translational medicine · 2024Review
- Iron-related Biomarkers in the Diagnosis and Management of Iron Disorders.Current medicinal chemistry · 2024Review
- The resistance to methoxy polyethylene glycol-epoetin beta in anemic patients of end-stage renal disease.Heliyon · 2023Article
- A Novel Combination Therapy of Erythropoietin and Thrombopoietin to Treat Erythropoietin-Resistance anemia.Pharmaceutical research · 2022Article
- Erythropoietin Resistance Development in Hemodialysis Patients: The Role of Oxidative Stress.Oxidative medicine and cellular longevity · 2022Article
- Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.Current research in pharmacology and drug discovery · 2022Article
- The Role of Reticulocyte Hemoglobin Content for the Diagnosis of Functional Iron Deficiency in Hemodialyzed patients.Saudi journal of biological sciences · 2021Article
- Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report.World journal of clinical cases · 2020Article
- Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives.International journal of nephrology and renovascular disease · 2020Review
- Clinical aspects and risk factors of lupus nephritis: a retrospective study of 156 adult patients.The Journal of international medical research · 2019Article
- Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Article
- Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.Pediatric nephrology (Berlin, Germany) · 2018Article
- Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study)Journal of clinical medicine · 2018Article
- Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to recombinant human erythropoietin is a common condition in dialyzed patients with chronic kidney disease and is associated with more hospitalizations, increased mortality and frequent blood transfusions. The main cause of hyporesponsiveness to recombinant human erythropoietin in these patients is iron deficiency. However, a high proportion of patients does not respond to treatment, even to the use of intravenous iron, which indicates the presence of other important causes of resistance. In addition to the iron deficiency, the most common causes of resistance include inflammation, infection, malnutrition, inadequate dialysis, and hyperparathyroidism, although other factors may be associated. In the presence of adequate iron stores, other causes should be investigated and treated appropriately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.